Kisunla targets early symptomatic Alzheimer’s, not halting but slowing cognitive decline by 35% over 18 months|Mo|CC BY-SA 4.0

The Food and Drug Administration (FDA) approved Eli Lilly’s Alzheimer’s drug, Kisunla, citing benefits in slowing disease progression despite risks.

The drug, priced at ~$12,522 for six months, aims to clear brain plaques linked to Alzheimer’s. It will compete with similar medicines by Biogen and Eisai that got approved in 2023.

Delayed since March for safety reviews, Kisunla targets early symptomatic Alzheimer’s, not halting but slowing cognitive decline by 35% over 18 months.  Yet, concerns linger about side effects such as brain swelling seen in trials.